A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Hepatology Année : 2017

A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)

(1) , (1) , (2, 3) , (4, 5) , (6) , (7) , (8) , (9) , (10) , (11, 12) , (13, 14) , (15) , (16, 17) , (18) , (19, 20) , (21, 22) , (23) , (24) , (25, 26) , (27) , (28, 29) , (30) , (31) , (1) , (3) , (1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Fichier non déposé

Dates et versions

hal-03590930 , version 1 (28-02-2022)

Identifiants

Citer

C. Corpechot, O. Chazouilleres, A. Rousseau, D. Guyader, F. Habersetzer, et al.. A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso). Journal of Hepatology, 2017, 66 (1, S), pp.S89. ⟨10.1016/S0168-8278(17)30442-7⟩. ⟨hal-03590930⟩
28 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More